Acme United (ACU) Q2 2026 Earnings Beat Margins Expand on MyMedic Integration

• Acme United (ACU) reported a significant Q2 2026 earnings beat, with EPS of $1.22 surpassing consensus estimates of $0.44.
• Revenue reached $62.72 million, reflecting a 16.15% year-over-year increase and beating expectations of $58.08 million .
• Consolidated gross margins expanded to 42.6% from 41.0% in the prior year, driven by the high-margin MyMedic product mix .
• Institutional investors significantly increased their positions in Q2, signaling continued confidence in growth.
• Management highlighted easing tariff pressures and strong free cash flow, though elevated SG&A expenses remain a near-term offset .

Acme United Corporation delivered a robust financial performance for the second quarter of 2026, significantly outperforming market expectations across key metrics. The company reported earnings per share of $1.22, which far exceeded the consensus estimate of $0.44 . This strong bottom-line result was supported by total revenue of $62.72 million, representing a 16.15% increase from the previous year and beating analyst forecasts of $58.08 million . The results reflect a 16.15% year-over-year revenue increase, with organic growth of 8% excluding the recent MyMedic acquisition .

A primary driver of this profitability was the significant expansion of consolidated gross margins to 42.6% in Q2 2026, up from 41.0% in the prior year period . This improvement is largely attributed to the inclusion of the higher-margin MyMedic business, which contributed approximately $4.3 million in Q2 sales while operating at breakeven . Management expects MyMedic profitability to improve significantly in Q4 due to seasonal demand, noting that roughly 35% of its sales typically occur in the fourth quarter .

Regional performance also contributed to the strong quarter. European sales surged by 19% in local currency, while U.S. segment sales increased by 17% . The U.S. growth was bolstered by renewed promotional activity in the Westcott cutting tools segment . However, the company faces headwinds from elevated selling, general, and administrative (SG&A) expenses, which reached 32% of sales due to advertising costs associated with the MyMedic brand .

How Are Tariff Pressures Impacting Acme United's Margins?

Acme United is navigating a complex tariff environment that has recently impacted its profitability. Prior tariff impacts reduced U.S. margins by approximately 100 basis points in Q2 . However, management provided visibility that these pressures should ease over the next two quarters .

The improvement is expected as higher-tariff inventory is gradually replaced by lower-cost stock throughout the remainder of the year . CEO Johnsen noted that tariff and freight costs ease, supporting further margin expansion. Despite these positive trends, investors should remain cautious of ongoing challenges from potential tariff and freight cost fluctuations .

Currency headwinds and uneven geographic performance, particularly with the Canadian market lagging behind other regions, also pose risks . The company generated approximately $15 million in free cash flow over the trailing twelve months, which is funding strategic investments including the $14 million MyMedic acquisition and capacity expansions for Spill Magic and MedNap .

What Is Driving Institutional Interest and Stock Momentum?

Institutional investors have shown increased confidence in Acme United during the second quarter. Bard Associates Inc. purchased 108,195 shares valued at approximately $5.16 million, making the stock its 24th largest position . Diamond Hill Capital Management LLC initiated a new stake, buying 34,092 shares worth roughly $1.63 million . Geode Capital Management also boosted its holding by 116.6% to 75,267 shares, while Jane Street Group increased its position by 61.0% .

Despite this institutional buying, insider activity was predominantly negative. Over the last 90 days, insiders sold a total of 23,247 shares valued at approximately $1.26 million . Director Brian Barker sold 3,821 shares at an average price of $0.50, while COO Brian S. Olschan sold 5,304 shares at $57.07 .

From a valuation perspective, ACU stock traded at $61.61 as of August 24, 2026, reflecting a 52.84% year-to-date gain . The stock's price-to-earnings ratio stands at 25.6, which is lower than the Health Care Equipment & Supplies industry median of 28.1 . Technical indicators show strong momentum, with a Momentum Score of 87 classified as 'Very Strong' .

The company maintains a low dividend yield of 1.0%, having recently paid a quarterly dividend of $0.16 . Institutional investors and hedge funds collectively own 62.10% of the stock, indicating substantial institutional backing . The next earnings report is scheduled for October 27, 2026, covering the period ending in September 2026 .